In contrast, another study of baseline ctDNA of advanced breast cancer patients treated with palbociclib or ribociclib found that patients with PIK3CA mutations had a shorter median PFS than wild-type[82]. The gene discussed is PIK3CA; the disease is breast carcinoma.